TRIANNI, Inc. (“Trianni”) and Takeda Pharmaceutical Company Limited (“Takeda”) jointly announced today that they have entered into a license agreement for Takeda’s use of the TRIANNI Mouse, a monoclonal antibody discovery platform. Distinguished by a novel chimeric gene segment design, the TRIANNI platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the isolation of fully human therapeutics.
“We are very pleased to see Takeda adopt the TRIANNI Mouse,” commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of Trianni. “With its many distinctive features, most notably a full repertoire expressed from chemically synthesized gene segments, we are confident the platform will prove highly productive for Takeda.”
“We are excited to add TRIANNI’s transgenic mice to Takeda’s repertoire of platform technologies for the generation of therapeutic antibodies,” said Tetsuyuki Maruyama, Ph.D., General Manager of Pharmaceutical Research Division of Takeda. “Takeda has a growing biologics pipeline and the TRIANNI Mouse is a natural addition to enhance our ongoing research capabilities in the area.”
About TRIANNI, Inc.
TRIANNI was formed in 2010 with a mission to exploit recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The TRIANNI Mouse. The company has administrative and research facilities in the San Francisco Bay Area and in Germany, respectively. Additional information about TRIANNI is available through its corporate website, www.trianni.com.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development.
The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Trianni nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.
Zishan Haroon, MD, PhD
Chief Business Officer
Director of Marketing
Takeda Pharmaceuticals International, Inc. Paul Graves
Takeda Pharmaceutical Company Limited Corporate Communications Dept. +81-3-3278-2037